/GLUE
GLUE Stock - Monte Rosa Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$15.54-1.83%
$0.29 (-1.83%) • Dec 19
81
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.56
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+41.6%upside
Target: $22.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GLUE
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$15.38 – $15.70
TARGET (TP)$22.00
STOP LOSS$14.30
RISK/REWARD1:5.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.60
52W High$19.17
52W Low$3.50
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $75.62M | N/A | N/A | N/A | N/A |
| Gross Profit | $67.50M | $-6,222,000 | N/A | N/A | $-537,000 |
| Gross Margin | 89.3% | N/A | N/A | N/A | N/A |
| Operating Income | $-81,112,000 | $-143,311,000 | $-112,384,000 | $-72,882,000 | $-28,010,000 |
| Net Income | $-72,700,000 | $-135,352,000 | $-108,501,000 | $-73,958,000 | $-35,879,000 |
| Net Margin | -96.1% | N/A | N/A | N/A | N/A |
| EPS | $-0.98 | $-2.63 | $-2.30 | $-1.59 | $-0.82 |
Company Overview
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
3
60%
Hold / Neutral
2
40%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
3 Bullish2 Neutral/Bearish
Price Targets
$17
Average Target
↑ 8.3% Upside
Now
$11
Low
$17
Average
$22
High
Based on 6 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 19th 2024 | Wells Fargo | Downgrade | Equal Weight | $11← $14 |
| February 15th 2024 | Wedbush | Initiation | Outperform | $11 |
| January 3rd 2023 | Wells Fargo | Upgrade | Overweight | $18 |
| October 13th 2022 | UBS | Initiation | Buy | $22 |
| August 15th 2022 | Jefferies | Initiation | Buy | $20 |
| April 28th 2022 | Credit Suisse | Initiation | Neutral | $19 |
Earnings History & Surprises
GLUEBeat Rate
78%
Last 18 quarters
Avg Surprise
-13.7%
EPS vs Estimate
Beats / Misses
14/4
Last 12 quarters
Latest EPS
$-0.33
Q4 2025
EPS Surprise History
Q1 24
-1.8%
$-0.58vs$-0.57
Q2 24
+5.4%
$-0.53vs$-0.56
Q3 24
+14.0%
$-0.43vs$-0.50
Q4 24
+35.6%
$-0.29vs$-0.45
Q1 25
+162.2%
$0.23vs$-0.37
Q2 25
+337.5%
$0.57vs$-0.24
Q3 25
+51.6%
$-0.15vs$-0.31
Q4 25
+15.4%
$-0.33vs$-0.39
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 6, 2026 | — | — | — | — |
Q1 2026 | Mar 19, 2026 | $-0.45 | — | — | — |
Q4 2025 | Nov 6, 2025 | $-0.39 | $-0.33 | +15.4% | ✓ BEAT |
Q3 2025 | Aug 7, 2025 | $-0.31 | $-0.15 | +51.6% | ✓ BEAT |
Q2 2025 | May 8, 2025 | $-0.24 | $0.57 | +337.5% | ✓ BEAT |
Q1 2025 | Mar 20, 2025 | $-0.37 | $0.23 | +162.2% | ✓ BEAT |
Q4 2024 | Nov 7, 2024 | $-0.45 | $-0.29 | +35.6% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.50 | $-0.43 | +14.0% | ✓ BEAT |
Q2 2024 | May 9, 2024 | $-0.56 | $-0.53 | +5.4% | ✓ BEAT |
Q1 2024 | Mar 14, 2024 | $-0.57 | $-0.58 | -1.8% | ✗ MISS |
Q4 2023 | Nov 9, 2023 | $-0.75 | $-0.70 | +6.7% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.72 | $-0.71 | +1.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.70 | $-0.65 | +7.1% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.64 | $-0.63 | +1.6% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-0.61 | $-0.58 | +4.9% | ✓ BEAT |
Q3 2022 | Aug 11, 2022 | $-0.54 | $-0.57 | -5.6% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-0.53 | $-0.51 | +3.8% | ✓ BEAT |
Q1 2022 | Mar 29, 2022 | $-0.50 | $-0.93 | -86.0% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.46 | $-0.43 | +6.5% | ✓ BEAT |
Q3 2021 | Aug 12, 2021 | $-0.40 | $-3.63 | -807.5% | ✗ MISS |
Latest News
Monte Rosa Therapeutics shares are trading higher after the company announced interim data from an ongoing Phase 1/2 clinical study evaluating MRT-2359 in combination with enzalutamide in heavily pretreated patients with metastatic castration-resistant prostate cancer. Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $13 to $22.
📈 PositiveBenzinga•Dec 16, 2025, 05:02 PM
Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Raises Price Target to $22
📈 PositiveBenzinga•Dec 16, 2025, 01:49 PM
Monte Rosa Therapeutics Shared Interim Data From An Ongoing Phase 1/2 Study Of MRT-2359 In Combination With Enzalutamide In Heavily Pretreated Patients With Metastatic Castration-resistant Prostate Cancer
➖ NeutralBenzinga•Dec 16, 2025, 12:04 PM
Monte Rosa Therapeutics To Present Interim Clinical Results From Ongoing Phase 1/2 Study Of GSPT1-Directed MGD MRT-2359 In mCRPC Patients In Live Conference Call On December 16
➖ NeutralBenzinga•Dec 15, 2025, 09:03 PM
Monte Rosa Therapeutics shares are trading higher after the company announced it will present preclinical data on the potential of MRT-8102.
📈 PositiveBenzinga•Nov 10, 2025, 05:38 PM
Reported Saturday, Monte Rosa Therapeutics Presents Preclinical Data At AHA 2025 Demonstrating MRT-8102 NEK7-Directed Molecular Glue Degrader Modulates NLRP3 Inflammasome In Cardiovascular And Cardiometabolic Diseases
📈 PositiveBenzinga•Nov 10, 2025, 09:03 AM
Wells Fargo Maintains Equal-Weight on Monte Rosa Therapeutics, Raises Price Target to $13
➖ NeutralBenzinga•Nov 7, 2025, 06:43 PM
Monte Rosa Therapeutics Q3 EPS $(0.33) Beats $(0.37) Estimate, Sales $12.768M Beat $5.420M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 01:01 PM
Monte Rosa Therapeutics Q3 Sales $12.768M Beat $5.420M Estimate
📈 PositiveBenzinga•Nov 6, 2025, 12:24 PM
Monte Rosa Therapeutics Unveils Preclinical Data Showing MRT-6160 Reduces Autoimmune Disease Markers; Supports Potential In SLE, Sjögren's, And RA; Phase 2 Planned With Novartis
📈 PositiveBenzinga•Oct 24, 2025, 11:04 AM•Also:
Monte Rosa Therapeutics shares are trading higher after the company announced a collaboration with Novartis to develop degraders for immune-mediated diseases.
📈 PositiveBenzinga•Sep 15, 2025, 11:50 AM•Also:
Market-Moving News for Sept 15
➖ NeutralBenzinga•Sep 15, 2025, 11:25 AM•Also: ,
Monte Rosa Therapeutics To Collaborate With Novartis To Develop Novel Degraders For Immune-Mediated Diseases
📈 PositiveBenzinga•Sep 15, 2025, 11:04 AM•Also:
Frequently Asked Questions about GLUE
What is GLUE's current stock price?
Monte Rosa Therapeutics, Inc. (GLUE) is currently trading at $15.54 per share. The stock has moved -1.83% today.
What is the analyst price target for GLUE?
The average analyst price target for GLUE is $22.00, based on 1 analyst.
What sector is Monte Rosa Therapeutics, Inc. in?
Monte Rosa Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GLUE's market cap?
Monte Rosa Therapeutics, Inc. has a market capitalization of $1.01 billion, making it a small-cap company.
Does GLUE pay dividends?
No, Monte Rosa Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorARVN
Arvinas, Inc.
$11.68
Mkt Cap: $0.8B
AVBP
ArriVent BioPharma, Inc. Common Stock
$22.01
Mkt Cap: $0.9B
DAWN
Day One Biopharmaceuticals, Inc.
$9.24
Mkt Cap: $0.9B
DNA
Ginkgo Bioworks Holdings, Inc.
$8.10
Mkt Cap: $0.4B
GERN
Geron Corporation
$1.33
Mkt Cap: $0.8B
MGTX
MeiraGTx Holdings plc
$8.03
Mkt Cap: $0.6B
REPL
Replimune Group, Inc.
$9.88
Mkt Cap: $0.8B
TBPH
Theravance Biopharma, Inc.
$18.79
Mkt Cap: $1.0B
VALN
Valneva SE
$8.07
Mkt Cap: $0.7B
VIR
Vir Biotechnology, Inc.
$5.76
Mkt Cap: $0.8B
Explore stocks similar to GLUE for comparison